Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity - 07/01/16
This work was supported by the German Research Council (grant no. HA 2393/6-1 to K.H.) and the Koeln Fortune Program, Faculty of Medicine, University of Cologne (grant no. 308/2014) to K.H. |
|
Disclosure of potential conflicts of interest: M. Arock has patents through CNRS (Centre national de la recherche scientifique) and ENS (Ecole normale supérieure de Cachan) Cachan for human mast cell lines, preparations, and uses (WO 2013064639 A1). U. Raap has received research support and payment for lectures from Novartis Pharma. K. Hartmann has consultant arrangements with Novartis; has received payment for lectures from Abbvie, Biogen, and Novartis; and has received a research grant from Novartis. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 1
P. 314 - janvier 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?